These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30149605)

  • 1. Association of Anabolic Effect of Calcitriol with Osteoclast-Derived Wnt 10b Secretion.
    Lu CL; Shyu JF; Wu CC; Hung CF; Liao MT; Liu WC; Zheng CM; Hou YC; Lin YF; Lu KC
    Nutrients; 2018 Aug; 10(9):. PubMed ID: 30149605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Effect of Calcimimetics on Osteoclast-Osteoblast Crosslink in Chronic Kidney Disease and Mineral Bone Disease.
    Hung KC; Chang JF; Hsu YH; Hsieh CY; Wu MS; Wu MY; Chiu IJ; Syu RS; Wang TM; Wu CC; Hung LY; Zheng CM; Lu KC
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease.
    Zheng CM; Hsu YH; Wu CC; Lu CL; Liu WC; Zheng JQ; Lin YF; Chiu HW; Chang TJ; Shyu JF; Lu KC
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.
    Sugatani T; Agapova OA; Fang Y; Berman AG; Wallace JM; Malluche HH; Faugere MC; Smith W; Sung V; Hruska KA
    Kidney Int; 2017 Jan; 91(1):86-95. PubMed ID: 27666759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of calcitriol and calcimimetic on bone health in renal insufficiency.
    Díaz-Tocados JM; Rodríguez-Ortiz ME; Herencia C; López-Baltanás R; Jurado-Montoya D; García-Saez RM; Valdés-Díaz K; Martínez-Moreno JM; Santamaría R; Pendón-Ruiz de Mier MV; Rodelo-Haad C; Frazão JM; Felsenfeld AJ; Rodríguez M; Almadén Y; Muñoz-Castañeda JR
    FASEB J; 2024 Jun; 38(11):e23726. PubMed ID: 38847773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic low dose tumor necrosis factor-α (TNF) suppresses early bone accrual in young mice by inhibiting osteoblasts without affecting osteoclasts.
    Gilbert LC; Chen H; Lu X; Nanes MS
    Bone; 2013 Sep; 56(1):174-83. PubMed ID: 23756233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
    Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
    J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo.
    Vandyke K; Dewar AL; Diamond P; Fitter S; Schultz CG; Sims NA; Zannettino AC
    J Bone Miner Res; 2010 Aug; 25(8):1759-70. PubMed ID: 20225261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTLA-4Ig (abatacept) balances bone anabolic effects of T cells and Wnt-10b with antianabolic effects of osteoblastic sclerostin.
    Roser-Page S; Vikulina T; Weiss D; Habib MM; Beck GR; Pacifici R; Lane TF; Weitzmann MN
    Ann N Y Acad Sci; 2018 Mar; 1415(1):21-33. PubMed ID: 29500936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro.
    Spencer GJ; Utting JC; Etheridge SL; Arnett TR; Genever PG
    J Cell Sci; 2006 Apr; 119(Pt 7):1283-96. PubMed ID: 16522681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased blood lead levels after calcitriol treatment in hemodialysis patients with secondary hyperparathyroidism.
    Lu KC; Wu CC; Ma WY; Chen CC; Wu HC; Chu P
    Bone; 2011 Dec; 49(6):1306-10. PubMed ID: 21985997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation.
    Wang X; Wu J; Shidoji Y; Muto Y; Ohishi N; Yagi K; Ikegami S; Shinki T; Udagawa N; Suda T; Ishimi Y
    J Bone Miner Res; 2002 Jan; 17(1):91-100. PubMed ID: 11771673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preservation of type H vessels and osteoblasts by enhanced preosteoclast platelet-derived growth factor type BB attenuates glucocorticoid-induced osteoporosis in growing mice.
    Yang P; Lv S; Wang Y; Peng Y; Ye Z; Xia Z; Ding G; Cao X; Crane JL
    Bone; 2018 Sep; 114():1-13. PubMed ID: 29800693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S; Wazny LD; Martin JE
    Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acceleration of bone regeneration by local application of lithium: Wnt signal-mediated osteoblastogenesis and Wnt signal-independent suppression of osteoclastogenesis.
    Arioka M; Takahashi-Yanaga F; Sasaki M; Yoshihara T; Morimoto S; Hirata M; Mori Y; Sasaguri T
    Biochem Pharmacol; 2014 Aug; 90(4):397-405. PubMed ID: 24955980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia.
    Ota M; Takahata M; Shimizu T; Kanehira Y; Kimura-Suda H; Kameda Y; Hamano H; Hiratsuka S; Sato D; Iwasaki N
    Osteoporos Int; 2017 Apr; 28(4):1481-1490. PubMed ID: 27933339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poligoni Multiflori Radix enhances osteoblast formation and reduces osteoclast differentiation.
    Han SY; Lee KH; Kim YK
    Int J Mol Med; 2018 Jul; 42(1):331-345. PubMed ID: 29620250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiscale effects of the calcimimetic drug, etelcalcetide on bone health of rats with secondary hyperparathyroidism induced by chronic kidney disease.
    Sharma S; Kumar S; Tomar MS; Chauhan D; Kulkarni C; Rajput S; Sadhukhan S; Porwal K; Guha R; Shrivastava A; Gayen JR; Kumar N; Chattopadhyay N
    Bone; 2024 Aug; 185():117126. PubMed ID: 38777312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.